IRIS
SPAGNUOLO, VINCENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 437
NA - Nord America 418
AS - Asia 279
SA - Sud America 6
AF - Africa 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.145
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 413
SE - Svezia 203
CN - Cina 147
SG - Singapore 112
IT - Italia 95
RU - Federazione Russa 81
FI - Finlandia 21
IE - Irlanda 13
IN - India 12
DE - Germania 9
BR - Brasile 6
NL - Olanda 5
CZ - Repubblica Ceca 4
PH - Filippine 4
CA - Canada 3
ID - Indonesia 2
LT - Lituania 2
TN - Tunisia 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
DO - Repubblica Dominicana 1
EU - Europa 1
FR - Francia 1
GB - Regno Unito 1
MD - Moldavia 1
PA - Panama 1
PT - Portogallo 1
VN - Vietnam 1
Totale 1.145
Salva come PNG Salva come JPEG
Città #
Lawrence 88
Princeton 88
New York 72
Singapore 65
Shanghai 46
Moscow 37
Milan 31
Boardman 30
Ashburn 29
Helsinki 19
Dublin 13
Guangzhou 10
Shenzhen 8
Beijing 7
Monza 5
Pune 5
Saint Louis 5
Monsummano Terme 4
Quanzhou 4
Quezon City 4
Seattle 4
Washington 4
Angera 3
Curitiba 3
Dallas 3
Los Angeles 3
Rome 3
Vittoria 3
Wuyuan 3
Xi'an 3
Borås 2
Duchcov 2
Durban 2
Forlì 2
Jakarta 2
Padova 2
Panchkula 2
Rio de Janeiro 2
Segrate 2
Torre Del Greco 2
Trieste 2
Tualatin 2
Varedo 2
Verona 2
Wuxi 2
Amsterdam 1
Baoding 1
Campodolcino 1
Canterbury 1
Cesano Maderno 1
Chisinau 1
Clifton 1
Cuneo 1
Dalian 1
Dalmine 1
Dongguan 1
Espoo 1
Faenza 1
Fuzhou 1
Hanover 1
Jiujiang 1
Kassel 1
Kunshan 1
Lainate 1
Lappeenranta 1
Lecco 1
Lisbon 1
Madignano 1
Messina 1
Mountain View 1
Munich 1
Nanjing 1
Ottawa 1
Paliano 1
Perugia 1
Pisa 1
Prague 1
Queens 1
Redwood City 1
San Sperate 1
Santa Maria A Monte 1
Stockholm 1
São Paulo 1
Torino 1
Toronto 1
Xiamen 1
Yangzhou 1
Totale 674
Salva come PNG Salva come JPEG
Nome #
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors 49
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 42
Brief Report: Association Between Low HIV-1 DNA and Western Blot Reactivity to HIV-1 Pol in Chronically Infected Individuals 29
High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19 28
Cerebrospinal fluid viral replication and burden of resistance in three HIV-1-infected people taking Ibalizumab with multiple drug class-wide resistance 23
HIV-DNA undetectability during chronic HIV infection: Frequency and predictive factors 23
Uberti Foppa C, Gaiera G, Nunzi E, Spagnuolo V Capitolo 101 Infezioni sistemiche in: Rugarli Medicina interna sistematica 23
INCREASED RISK OF DEATH AMONG HIV/HCV CO-INFECTED PATIENTS WITH NON-HODGKIN'S LYMPHOMA 22
Analytical treatment interruption in chronic HIV-1 infection: Time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study) 22
Analysis of the faecal microbiome during analytical treatment interruption in people with chronic HIV infection and long-lasting virological suppression (APACHE study) 22
Meningococcus B Vaccination Effectiveness Against Neisseria gonorrhoeae Infection in People Living With HIV: A Case-Control Study 21
Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients 20
Cardiac implantable electronic device infections: impact of initiation of antimicrobial treatment before or after device removal on microbiological yield 19
Cardiovascular risk and dyslipidemia among persons living with HIV: A review 19
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection 18
Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial 18
Awareness, discussion and non-prescribed use of HIV pre-exposure prophylaxis among persons living with HIV/AIDS in Italy: A Nationwide, cross-sectional study among patients on antiretrovirals and their treating HIV physicians 18
Neutralizing monoclonal antibodies for the treatment and prophylaxis of SARS-CoV-2 infection 18
Treatment success of rescue regimens after dual therapy failure in people living with HIV in a real-life setting 18
Bictegravir 17
Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimens 17
Clinical outcomes of two-drug regimens vs. three-drug regimens in antiretroviral treatment-experienced people living with HIV 17
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection-authors' response 16
An observational, retrospective analysis evaluating switching to raltegravir plus abacavir/lamivudine in HIV-1-infected patients: the ORASWIRAL study 16
Increased dose of dolutegravir as a potential rescue therapy in multi-experienced patients 16
A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study 16
Impact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study 15
Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir 15
Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patients 15
Brief Report: Hyperbilirubinemia Is Associated With a Decreased Risk of Carotid Atherosclerosis in HIV-Infected Patients on Virological Suppression 15
Exercise ECG for coronary artery disease screening in people living with HIV: The cordis STUDY 15
Increasing incidence and prevalence of metabolic syndrome in people living with HIV during the COVID-19 pandemic 14
Liver function parameters in HIV/HCV co-infected patients treated with amprenavir and ritonavir and correlation with plasma levels 14
Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients 14
Changes in Darunavir/r Resistance Score After Previous Failure to Tipranavir/r in HIV-1-Infected Multidrug-Resistant Patients 13
Non-Hodgkin lymphoma risk in adults living with HIV across five continents 13
FAILURE TO DARUNAVIR/RITONAVIR CAN EITHER INCREASE OR DECREASE TIPRANAVIR/RITONAVIR GENOTYPIC RESISTANCE SCORE IN HIGHLY TREATMENT-EXPERIENCED HIV-INFECTED PATIENTS 13
Evaluation of HIV transmission clusters among natives and foreigners living in Italy 13
Long-term suppression of viral replication in HIV-related lymphoma survivors: a case-control study 13
Monotherapy with atazanavir as a simplification strategy: results from an observational study. 12
Use of statins and aspirin to prevent cardiovascular disease among HIV-positive patients. A survey among Italian HIV physicians 12
Four-year outcome of a PI and NRTI-sparing salvage regimen: maraviroc, raltegravir, etravirine 12
Chronic hepatitis B and C virus infection and risk for non-hodgkin lymphoma in HIV-infected patients: A cohort study 12
LONG-TERM SURVIVAL AMONG HIV-1 INFECTED PATIENTS WITH AIDS AND NON AIDS RELATED MALIGNANCIES 12
Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy 11
Cerebrospinal fluid markers in long-term atazanavir/ritonavir monotherapy 11
Plasma fibroblast growth factor 23 and osteocalcin serum levels are associated with cardiovascular risk in HIV-1-infected patients receiving antiretroviral treatment. 11
Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption 11
Treatment simplification to atazanavir/ritonavir+lamivudine versus maintenance of atazanavir/ritonavir+two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 11
HIV Glasgow 2018, 28-31 October 2018, Glasgow, UK 11
Should we expect weight changes in people with HIV and a reported weight gain only by switching antiretroviral therapy? 10
Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL 10
Immune recovery and T cell subset analysis during effective treatment with maraviroc 10
Changing Incidence and Risk Factors for Kaposi Sarcoma by Time since Starting Antiretroviral Therapy: Collaborative Analysis of 21 European Cohort Studies 10
Potential associations between atazanavir exposure and clinical outcome: a pharmacokinetic sub-study from the MODAt randomized trial 10
Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen 10
Clinical, virologic, and immunologic outcomes in lymphoma survivors and in cancer-free, HIV-1-infected patients: a matched cohort study. 10
High plasma levels of parathyroid hormone (PTH) are associated with an increased cardiovascular risk among HIV-infected subjects 10
LONG TERM CD4 RECOVERY IN FULLY SUPPRESSED SUBJECTS TREATED WITH FIRST LINE HAART IS INFLUENCED BY TIME TO REACH UNDETECTABILITY 10
PHENOTYPIC PROFILES OF HIV-1 INTEGRASE GENE EVOLUTION DURING RALTEGRAVIR FAILURE 10
Inflammation burden score in multidrug-resistant HIV-1 infection 9
Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry 9
Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies 9
Immortal time bias: authors' reply 9
Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy 9
Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients 9
Evolution of HIV-1 transmitted drug resistance in Italy in the 2007–2014 period: A weighted analysis 9
Integrase and Fusion Inhibitors Transmitted Drug Resistance in Naive Patients With Recent Diagnosis of HIV-1 Infection 9
Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting 9
Influence of gender in predicting CCR5 coreceptor usage 9
Cross-resistance Profile of the Novel Integrase Inhibitor Dolutegravir (S/GSK1349572) Using Clonal Viral Variants Selected in Patients Failing Raltegravir 8
Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results 8
Mortality of HIV-infected patients with or without cancer: comparison with the general population in Italy 8
Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients 8
Immune response to hepatitis B vaccination in HIV-positive individuals with isolated antibodies against hepatitis B core antigen: Results of a prospective Italian study 8
Darunavir for the treatment of HIV infection 8
Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens 8
Pharmacotherapeutic management of HIV in transplant patients 8
Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium 8
HIV DNA loads, plasma residual viraemia and risk of virological rebound in heavily treated, virologically suppressed HIV-infected patients. 7
Optimal dietary calcium intake in HIV treated patients: No femoral osteoporosis but higher cardiovascular risk 7
Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study 7
Unboosted atazanavir with lamivudine/emtricitabine for patients with long-lasting virological suppression 7
Levels of soluble endothelial protein C receptor are associated with CD4+ changes in Maraviroc-treated HIV-infected patients. 7
Prior therapy influences the efficacy of lamivudine monotherapy in patients with lamivudine-resistant HIV-1 infection. 7
Glucose tolerance in HIV-1 treated patients who switched from boosted-protease inhibitors to etravirine 7
Statins and aspirin in the prevention of cardiovascular disease among HIV-positive patients between controversies and unmet needs: Review of the literature and suggestions for a friendly use 7
Is statin preventing cancer in HIV-1 infected individuals? An inappropriate methodology is a more likely explanation: authors' reply 6
Is there any potential for first-line etravirine use? Analysis from a large data set of antiretroviral therapy-naive HIV-infected patients undergoing resistance test. 6
Glomerular filtration rate estimated by cystatin C formulas in HIV-1 patients treated with dolutegravir, rilpivirine or cobicistat 6
Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mLauthors response 6
Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral-naïve persons starting treatment 6
Virological rebound in human immunodeficiency virus-infected patients with or without residual viraemia: results from an extended follow-up 5
Incidence and Predictors of Serological Treatment Response in Early and Late Syphilis Among People Living With HIV 5
Predictors of lack of serological response to syphilis treatment in HIV-infected subjects 5
PRESTIGIO RING: "A 59-year-old HIV-1 positive, highly treatment-experienced woman failing darunavir/ ritonavir plus raltegravir" 5
Ten-year survival among HIV-1-infected subjects with AIDS or non-AIDS-defining malignancies 4
Management of HIV infection after triple class failure 4
One Year of Long-Acting Cabotegravir and Rilpivirine in People With Human Immunodeficiency Virus and Long Exposure to Antiretroviral Therapy: Data From the SCohoLART Study 3
Long-term outcome in a person with pandrug-resistant HIV: the added value of a multidisciplinary approach 2
Totale 1.256
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.165
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.165
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202136 0 0 0 5 0 10 1 17 2 0 1 0
2021/202269 0 0 0 18 9 9 2 6 6 4 9 6
2022/2023410 190 89 24 4 7 35 18 27 15 0 0 1
2023/2024354 6 13 54 21 36 100 5 34 1 4 25 55
2024/2025339 170 21 27 59 62 0 0 0 0 0 0 0
Totale 1.264